News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,392 Results
Type
Article (40519)
Company Profile (268)
Press Release (673600)
Multimedia
Podcasts (73)
Webinars (17)
Section
Business (204516)
Career Advice (2017)
Deals (35492)
Drug Delivery (102)
Drug Development (81262)
Employer Resources (173)
FDA (16324)
Job Trends (14923)
News (346001)
Policy (32687)
Tag
Academia (2558)
Accelerated approval (15)
Adcomms (24)
Allergies (118)
Alliances (49573)
ALS (134)
Alzheimer's disease (1563)
Antibody-drug conjugate (ADC) (229)
Approvals (16436)
Artificial intelligence (405)
Autoimmune disease (91)
Automation (30)
Bankruptcy (361)
Best Places to Work (11637)
BIOSECURE Act (20)
Biosimilars (152)
Biotechnology (175)
Bladder cancer (133)
Brain cancer (45)
Breast cancer (501)
Cancer (3915)
Cardiovascular disease (321)
Career advice (1699)
Career pathing (33)
CAR-T (231)
CDC (42)
Cell therapy (616)
Cervical cancer (31)
Clinical research (68343)
Collaboration (1331)
Company closure (4)
Compensation (940)
Complete response letters (44)
COVID-19 (2683)
CRISPR (74)
C-suite (578)
Cystic fibrosis (131)
Data (4863)
Decentralized trials (2)
Denatured (24)
Depression (96)
Diabetes (432)
Diagnostics (6549)
Digital health (34)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (189)
Drug pricing (157)
Drug shortages (28)
Duchenne muscular dystrophy (196)
Earnings (89302)
Editorial (47)
Employer branding (21)
Employer resources (151)
Events (115727)
Executive appointments (928)
FDA (18809)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1206)
Gene editing (162)
Generative AI (31)
Gene therapy (491)
GLP-1 (883)
Government (4607)
Grass and pollen (6)
Guidances (370)
Healthcare (18857)
HIV (43)
Huntington's disease (36)
IgA nephropathy (65)
Immunology and inflammation (212)
Immuno-oncology (17)
Indications (59)
Infectious disease (2910)
Inflammatory bowel disease (175)
Inflation Reduction Act (13)
Influenza (94)
Intellectual property (194)
Interviews (315)
IPO (16613)
IRA (48)
Job creations (3639)
Job search strategy (1427)
Kidney cancer (15)
Labor market (74)
Layoffs (534)
Leadership (28)
Legal (7940)
Liver cancer (85)
Longevity (11)
Lung cancer (555)
Lymphoma (280)
Machine learning (30)
Management (59)
Manufacturing (600)
MASH (137)
Medical device (13638)
Medtech (13665)
Mergers & acquisitions (19775)
Metabolic disorders (1066)
Multiple sclerosis (134)
NASH (16)
Neurodegenerative disease (203)
Neuropsychiatric disorders (50)
Neuroscience (2538)
NextGen: Class of 2025 (6518)
Non-profit (4495)
Now hiring (59)
Obesity (499)
Opinion (240)
Ovarian cancer (140)
Pain (154)
Pancreatic cancer (172)
Parkinson's disease (230)
Partnered (29)
Patents (410)
Patient recruitment (330)
Peanut (52)
People (58284)
Pharmaceutical (63)
Pharmacy benefit managers (25)
Phase I (21273)
Phase II (30077)
Phase III (22430)
Pipeline (2946)
Policy (248)
Postmarket research (2564)
Preclinical (9078)
Press Release (64)
Prostate cancer (194)
Psychedelics (42)
Radiopharmaceuticals (257)
Rare diseases (619)
Real estate (5936)
Recruiting (69)
Regulatory (23543)
Reports (51)
Research institute (2356)
Resumes & cover letters (351)
Rett syndrome (17)
RNA editing (11)
RSV (68)
Schizophrenia (126)
Series A (195)
Series B (149)
Service/supplier (11)
Sickle cell disease (76)
Special edition (21)
Spinal muscular atrophy (149)
Sponsored (36)
Startups (3600)
State (2)
Stomach cancer (15)
Supply chain (94)
Tariffs (79)
The Weekly (47)
Vaccines (912)
Venture capital (65)
Weight loss (324)
Women's health (58)
Worklife (17)
Date
Today (15)
Last 7 days (1055)
Last 30 days (3128)
Last 365 days (30528)
2025 (26290)
2024 (35218)
2023 (40076)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (730)
Alabama (72)
Alaska (7)
Arizona (275)
Arkansas (13)
Asia (38720)
Australia (6329)
California (9602)
Canada (2889)
China (877)
Colorado (398)
Connecticut (410)
Delaware (271)
Europe (83457)
Florida (1428)
Georgia (307)
Hawaii (2)
Idaho (60)
Illinois (724)
India (49)
Indiana (461)
Iowa (18)
Japan (325)
Kansas (120)
Kentucky (34)
Louisiana (20)
Maine (69)
Maryland (1246)
Massachusetts (6980)
Michigan (286)
Minnesota (552)
Mississippi (4)
Missouri (111)
Montana (29)
Nebraska (25)
Nevada (104)
New Hampshire (72)
New Jersey (2628)
New Mexico (28)
New York (2572)
North Carolina (1282)
North Dakota (8)
Northern California (4521)
Ohio (287)
Oklahoma (20)
Oregon (37)
Pennsylvania (2005)
Puerto Rico (19)
Rhode Island (43)
South America (1099)
South Carolina (50)
South Dakota (1)
Southern California (3693)
Tennessee (149)
Texas (1470)
United States (34583)
Utah (285)
Virginia (225)
Washington D.C. (77)
Washington State (793)
West Virginia (4)
Wisconsin (82)
Wyoming (2)
714,392 Results for "idrx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GSK Enters Agreement to Acquire IDRx, Inc.
January 13, 2025
·
8 min read
Drug Development
IDRx Reports Updated Preliminary Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial Supporting Best-in-Class Potential for IDRX-42 in Patients with GIST
IDRx, Inc. announced updated preliminary clinical data from the Phase 1 portion of the company’s ongoing StrateGIST 1 study of IDRX-42 in patients with advanced gastrointestinal stromal tumors.
June 3, 2024
·
8 min read
Business
IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer
IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.
March 27, 2024
·
3 min read
Mergers & acquisitions
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
January 13, 2025
·
2 min read
·
Tristan Manalac
Business
IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO
IDRx, Inc. announced that it has strengthened its leadership team with the appointments of Tim Clackson, Ph.D. as Chief Executive Officer, and Brad Dahms as Chief Financial Officer and Chief Business Officer.
March 12, 2024
·
6 min read
Drug Development
IDRx Presents Preliminary Clinical Data from Ongoing Phase 1 StrateGIST Study at CTOS 2023 Supporting Best-in-Class Potential of IDRX-42 in Patients with GIST
IDRx, Inc. announced preliminary clinical data from the dose escalation portion of the company’s ongoing Phase 1 StrateGIST study of IDRX-42 in patients with metastatic and/or unresectable gastrointestinal stromal tumors who have previously received one or more prior lines of tyrosine kinase inhibitor therapy.
November 2, 2023
·
7 min read
Press Releases
IDRx Announces Updated Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial of IDRX-42 in Advanced Gastrointestinal Stromal Tumors (GIST) at CTOS 2024
November 14, 2024
·
9 min read
Business
C-Suite Shuffle: Sumitomo, Kineta, IDRx and More
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
March 13, 2024
·
6 min read
·
Neil Versel
Genetown
IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapies
IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched with a $122 million oversubscribed Series A financing.
August 2, 2022
·
4 min read
Business
With $122M, Startup IDRx Intends to Stop Cancer Mutations in their Tracks
IDRx aims to create highly selective and aligned drug combinations to stop key tumor escape mechanisms that will support prolonged and durable responses to therapy.
August 2, 2022
·
3 min read
·
Vanessa Doctor, RN
1 of 71,440
Next
